PR Newswire BiotechnologyQwen · 实盘不做把握 2/10不做原因:不是事件
北京时间·🕒 发布 18:59:00·⟳ 抓取 18:59:22 +22s·⚡ 决策 09-01 19:08:13 +8m51s·56.3 天前
Q32 Bio宣布管理层将参加9月三场投资者会议
这是一份标准的投资者会议参加公告（conference participation announcement），仅告知管理层将在三场行业会议上做Fireside Chat展示。公告不包含任何新增临床数据、监管审批进展、商业合作、财务指引或业务变动信息。此类公告是生物科技公司常规IR活动，历史上不会对股价产生可交易的方向性影响。
📄 原文PR Newswire Biotechnology↗ 原文
Q32 Bio to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology c…
不做 Q32 Bio Inc.（QTTB.US）
例行投资者会议参加公告，无新增临床数据、监管进展、合作或财务指引，不构成可交易催化事件，无方向性edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Q32 Bio于9月1日发布例行公告，宣布管理层将参加9月8日、9日和15日的三场医疗健康投资者会议。公告内容仅为会议日程安排，无任何新增管线数据、监管里程碑、合作或财务信息。投资者会议参加公告是美股生物科技公司最常见的IR披露类型之一，不构成股价催化事件，无可交易方向或edge。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 681 ms
{"result": "search_processed_events:agent query=`q32 bio investor conference participation | qttb conference september 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 61.5/72 小时、2063 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 2,891 字
WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate in three upcoming investor conferences in September:
Wells Fargo 21st Annual Healthcare Conference
Date: Tuesday, September 8, 2026
Fireside Chat Presentation Time: 3:45 p.m. E.T.
Location: Boston, MA
Cantor Global Healthcare Conference 2026
Date: Wednesday, September 9, 2026
Fireside Chat Presentation Time: 3:55 p.m. E.T.
Location: New York, NY
Morgan Stanley 24th Annual Global Healthcare Conference
Date: Tuesday, September 15, 2026
Fireside Chat Presentation Time: 11:30 a.m. E.T.
Location: New York, NY
A webcast of each presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following each event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
1National Alopecia Areata Foundation
Availability of Other Information About Q32 Bio
Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Contacts:
Investors: Brendan Burns
Argot Partners
212.600.1902
[email protected]
Media: David Rosen
Argot Partners
646.461.6387
[email protected]
SOURCE Q32 Bio
Wells Fargo 21st Annual Healthcare Conference
Date: Tuesday, September 8, 2026
Fireside Chat Presentation Time: 3:45 p.m. E.T.
Location: Boston, MA
Cantor Global Healthcare Conference 2026
Date: Wednesday, September 9, 2026
Fireside Chat Presentation Time: 3:55 p.m. E.T.
Location: New York, NY
Morgan Stanley 24th Annual Global Healthcare Conference
Date: Tuesday, September 15, 2026
Fireside Chat Presentation Time: 11:30 a.m. E.T.
Location: New York, NY
A webcast of each presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following each event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata1, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
1National Alopecia Areata Foundation
Availability of Other Information About Q32 Bio
Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Contacts:
Investors: Brendan Burns
Argot Partners
212.600.1902
[email protected]
Media: David Rosen
Argot Partners
646.461.6387
[email protected]
SOURCE Q32 Bio
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。